Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Conditions
Brief summary
Extranodal natural killer/T-cell lymphoma, nasal type (NKTCL) is a highly aggressive peripheral T-cell lymphoma (PTCL). Patients with newly diagnosed stage IV and relapsed/refractory have poor prognosis. 5-year progression-free survival was reported only 55%. Chidamide is a selective histone deacetylase inhibitor which was approved by FDA in treating relapsed or refractory PTCL. In phase I and II studies of chidamide, patients with relapsed or refractory NKTCL achieved a higher overall remission. Patients who obtained complete or partial remission had much favourable duration of remission. Thus, the invesgator design this study to evaluate the role of maintenance treatment of chidamide for induction chemotherapy-responded newly-diagnosed advanced and relapsed/refractory NKTCL patients.
Interventions
DRUGchidamide
For those who responded to induction chemotherapy, chidamide will be given OR orally 30mg biw for at least half a year
Sponsors
Chinese Academy of Medical Sciences
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. diagnosis of NKTCL with typical morphology and immunophenotype, according to the 2008 World Health Organization classification of lymphomas; 2. newly-diagnosed stage IV disease or relapsed or refractory disease； 3. age ≥ 18 years; 4. ECOG performance status 0-2; 5. at least one measurable lesion; 6. adequate hematological, hepatic, and renal functions; e.g., absolute neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 80 × 109/L, total bilirubin ≤ 1.5 × upper limit of normal, alanine transaminase and aspartate transaminase ≤ 2 × upper limit of normal, and creatinine ≤ 1.5 mg/dl; 7. life expectancy of more than 3 months.
Exclusion criteria
1. Patients with newly-diagnosed stage I-II disease; 2. pregnancy or lactation; 3. any coexisting medical problems of sufficient severity to prevent full compliance with the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 1 year | PFS was defined as the period from the date of treatment till the date of disease progression, relapse, or death from any cause. |
Countries
China
Contacts
Primary ContactMei Dong
Outcome results
None listed